Ervebo Market Report 2026

Ervebo Market Overview

• The Ervebo market growth in the historic period has been driven by recurring ebola outbreaks in africa, high mortality rates of ebola virus disease • Market expansion is supported by strengthening of global pandemic preparedness, expansion of government vaccine stockpiles • Growth Driver: Rising Viral Infections Drive Growth In The Market • Market Trend: Key Developments In The Ervebo Ebola Vaccine Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Ervebo Market?

Ervebo is a recombinant, live vaccine developed to protect against ebola virus disease caused by the zaire ebolavirus species. It is administered as a single-dose injection and has been pivotal in controlling outbreaks, particularly through ring vaccination strategies in affected regions. The main clinical indications of ervebo are general immunization and geographically targeted vaccination. General immunization refers to the widespread administration of vaccines to protect against common infectious diseases. It is distributed through hospital pharmacies and retail pharmacies and caters to various end users, including adults and geriatrics.

What Is The Ervebo Market Growth Forecast?

The growth in the forecast period can be attributed to strengthening of global pandemic preparedness, expansion of government vaccine stockpiles, rising international health collaborations, increased focus on zoonotic diseases, faster regulatory approvals for emergency vaccines. Major trends in the forecast period include expansion of ring vaccination strategies, focus on outbreak preparedness vaccines, global stockpiling of critical vaccines, single-dose vaccine development, public health emergency immunization programs.

Global Ervebo Market Segmentation

1) By Clinical Indication: General Immunization, Geographically Targeted Vaccination 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Ervebo Market?

The increasing incidence of viral infections is expected to fuel the growth of the ervebo market going forward. A viral infection is the invasion and replication of a virus within a host's cells, causing disease that varies in severity depending on the virus and the immune response. Increasing viral infections are fueled by global travel, which facilitates the rapid spread of viruses across borders, and climate change, which alters ecosystems, creating conditions for new viruses to emerge. Ervebo is used to prevent viral infections by vaccinating at-risk populations during outbreaks, typically through ring vaccination strategies to control the spread of the Zaire ebolavirus. For instance, in January 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, between 20 September 2022 and 10 January 2023, a total of 4,793 contacts were identified, and 11,025 alerts were reported. Of these, 8,088 alerts (73%) were investigated, and 7,382 (67%) were confirmed as suspected cases of Ebola disease caused by the Sudan ebolavirus. Therefore, the increasing incidence of viral infections is driving the growth of the ervebo industry. The increasing investments in healthcare are anticipated to drive the future growth of the ervebo market. Healthcare investments refer to the allocation of financial resources toward entities, technologies, services, or innovations in the healthcare sector. Healthcare investments are rising due to increasing demand for chronic disease management from aging populations and funding for advanced technologies such as telemedicine and AI to improve healthcare delivery. Healthcare investments contribute significantly to the success and development of the ervebo Ebola vaccine by supporting research, clinical trials, production, and distribution. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, rising investments in healthcare are driving the growth of the ervebo industry.

Key Players In The Global Ervebo Market

Major companies operating in the ervebo market are Merck & Co. Inc.

Global Ervebo Market Trends and Insights

The key trend in the ervebo market is the pursuit of regulatory drug approvals to broaden its availability and enhance its global reach. Regulatory drug approvals involve a formal process where national or international health authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), evaluate and authorize a new drug or vaccine for public use. For instance, in August 2023, Merck and Co. Inc., a US-based pharmaceutical company, received approval from the FDA for ERVEBO (Ebola Zaire Vaccine, Live), allowing its administration in children aged 12 months and older. This vaccine is highly effective 100% effective when given more than ten days before exposure to the Ebola virus. It is a live recombinant viral vaccine that prompts an immune response without causing the disease. This approval addresses the urgent need for vaccination in younger populations at risk of Ebola virus disease, especially highlighted by past outbreaks where children comprised a significant portion of the affected cases.

Regional Insights

North America was the largest region in the ervebo market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ervebo Market?

The ervebo market consists of sales of products including pre-filled vaccine syringes, cold chain storage solutions, vaccination kits, and training and education materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ervebo Market Report 2026?

The ervebo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ervebo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.